Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Oct 6;81(3):543-546.
doi: 10.1093/cid/ciaf120.

Long-Acting Injectable HIV Therapy Outcomes Among Persons With HIV Who Have Adherence Challenges to Oral Antiretroviral Therapy

Elizabeth Hastie  1 , Lucas Hill  1 , Laura Bamford  1 , Afsana Karim  1 , Thomas C S Martin  1   2
Affiliations
Observational Study

Long-Acting Injectable HIV Therapy Outcomes Among Persons With HIV Who Have Adherence Challenges to Oral Antiretroviral Therapy

Elizabeth Hastie et al. Clin Infect Dis. .

Abstract

Long-acting injectable cabotegravir/rilpivirine (LAI-CAB/RPV) may improve outcomes among persons with human immunodeficiency virus (PWH) with adherence difficulties to oral therapy. In this real-world observational study, over 85% of PWH remained on therapy and virally suppressed 48 weeks after initiating LAI-CAB/RPV. Providers should consider LAI therapy among PWH with adherence difficulties.

Keywords: adherence challenges; cabotegravir-rilpivirine; long-acting injectables; people with HIV; viremia.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier survival free from either virological failure (viral load ≥ 200 copies/mL) or discontinuation of long-acting injectable cabotegravir/rilpivirine (LAI-CAB/RPV) among persons with human immunodeficiency virus with adherence difficulties who initiated LAI CAB/RPV.
See this image and copyright information in PMC

References

    1. Scarsi KK, Swindells S. The promise of improved adherence with long-acting antiretroviral therapy: what are the data? J Int Assoc Provid AIDS Care 2021; 20:23259582211009011. - PMC - PubMed
    1. Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd LA. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother 2022; 77:290–302. - PMC - PubMed
    1. Gandhi M, Hill L, Grochowski J, et al. Case series of people with HIV on the long-acting combination of lenacapavir and cabotegravir: call for a trial. Open Forum Infect Dis 2024; 11:ofae125. - PMC - PubMed
    1. Nachega JB, Scarsi KK, Gandhi M, et al. Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV 2023; 10:e332–42. - PMC - PubMed
    1. Venkatesan P. Long-acting injectable ART for HIV: a (cautious) step forward. Lancet Microbe 2022; 3:e94. - PubMed

Publication types